1. Home
  2. FIEE vs VERU Comparison

FIEE vs VERU Comparison

Compare FIEE & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FiEE Inc

FIEE

FiEE Inc

N/A

Current Price

$5.19

Market Cap

45.6M

Sector

Utilities

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.25

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIEE
VERU
Founded
1977
1971
Country
Hong Kong
United States
Employees
43
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.6M
40.9M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
FIEE
VERU
Price
$5.19
$2.25
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
6.6K
63.0K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.50
$0.36
52 Week High
$7.95
$4.59

Technical Indicators

Market Signals
Indicator
FIEE
VERU
Relative Strength Index (RSI) 40.08 46.97
Support Level $2.40 $2.12
Resistance Level $7.28 $2.67
Average True Range (ATR) 0.36 0.13
MACD -0.07 0.02
Stochastic Oscillator 37.40 55.71

Price Performance

Historical Comparison
FIEE
VERU

About FIEE FiEE Inc

FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: